Mitapivat: all 28 studies that test it

Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.

• A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)RecruitingNCT07656415Phase 3
• A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent ThalassemiaRecruitingNCT07517133Phase 3
• A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)RecruitingNCT07506863Phase 3
• Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte MembranopathiesNot yet recruitingNCT05935202Phase 2
• A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat StudyEnrolling by invitationNCT05777993Phase 4
• A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)Active, not recruitingNCT04770779Phase 3Results posted
• A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)Active, not recruitingNCT04770753Phase 3Results posted
• A Dose-Finding Study of AG-348 in Sickle Cell DiseaseCompletedNCT04000165Early Phase 1Results posted
• Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007CompletedNCT03853798Phase 3Results posted
• A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent ThalassemiaActive, not recruitingNCT03692052Phase 2Results posted
• A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)CompletedNCT03559699Phase 3Results posted
• A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)CompletedNCT03548220Phase 3Results posted
• A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) DeficiencyCompletedNCT02476916Phase 2Results posted
• To Assess Safety of Mitapivat and Provide Proof of Concept of the Efficacy of the Drug in Patients With RBC Membranopathies or CDAII.Active, not recruitingNCT07055243Phase 2
• Study of How Mitapivat Affects Midazolam Blood Levels in Healthy ParticipantsCompletedNCT06648824Phase 1
• A Study of Mitapivat in Participants With Sickle Cell Disease and NephropathyWithdrawnNCT06286046Phase 2
• A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic FunctionCompletedNCT05610657Phase 1
• A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension PeriodActive, not recruitingNCT05175105Phase 3
• A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension PeriodActive, not recruitingNCT05144256Phase 3
• A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)Active, not recruitingNCT05031780Phase 2/3
• A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult ParticipantsCompletedNCT04696393Phase 1
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of MitapivatActive, not recruitingNCT04610866Phase 1/2
• A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy ParticipantsCompletedNCT04565678Phase 1
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult ParticipantsCompletedNCT04472832Phase 1
• A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348CompletedNCT03703505Phase 1
• Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origin and Non-Asian OriginCompletedNCT03250598Phase 1
• A Phase I Study of AG-348 in Healthy VolunteersCompletedNCT02149966Phase 1
• A Phase I Study of AG-348 in Healthy VolunteersCompletedNCT02108106Phase 1

← Mitapivat overview